Improving screening for liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study aims to compare the effectiveness of ultrasound versus abbreviated magnetic resonance imaging (AMRI) in detecting hepatocellular carcinoma (HCC) in patients with chronic liver disease. Participants will undergo screening rounds that include both ultrasound and MRI within the same week, conducted bi-annually. The study hypothesizes that AMRI with a contrast agent will yield a higher detection rate of HCC compared to routine ultrasound screenings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations.
* Informed Consent signed by the subject

Exclusion Criteria:

* History of HCC
* History of other malignancy
* Prior liver nodule categorized as LI-RAD 4, 5 or M
* History of liver transplantation
* Pregnancy
* MRI or MRI contrast agent precaution
* Any other condition making the patient unsuitable for the study
* Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study

Where it's running

• Lausanne University Hospital
  Lausanne, Canton of Vaud, Switzerland Recruiting

Study contacts

• Principal investigator: Naik Vietti Violi, MD — University of Lausanne Hospitals
• Study coordinator: Naik Vietti Violi, MD
• Email: naik.vietti-violi@chuv.ch
• Phone: +41213144556

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)

  This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.

  Recruiting AstraZeneca · Al Mansurah and 16 other locations · NCT07650773

• GLP-1 RA plus standard treatment in first-line metastatic GI cancers

  This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.

  Recruiting Early Phase 1 University of Arizona · Tucson, Arizona · NCT07627191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.